JAMA & ARCHIVES
Arch Fam Med
SEARCH
GO TO ADVANCED SEARCH
HOME  PAST ISSUES  TOPIC COLLECTIONS  CME  PHYSICIAN JOBS  CONTACT US  HELP
Institution: CLOCKSS  | My Account | E-mail Alerts | Access Rights | Sign In
  Vol. 4 No. 12, December 1995 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Use of Warfarin for Nonvalvular Atrial Fibrillation in Nursing Home Patients

Thomas E. Lackner, PharmD; George N. Battis, MD

Arch Fam Med. 1995;4(12):1017-1026.


Abstract

Objective
To assess warfarin sodium use and anticoagulant monitoring in nursing home patients with nonvalvular atrial fibrillation (NVAF), according to American College of Chest Physicians Consensus Conference guidelines.

Design
Retrospective, multicenter, point-prevalence study.

Setting
Nursing homes in Minneapolis—St Paul, Minn.

Patients
Nine-hundred two patients 60 years and older, from whom 69 with a diagnosis of NVAF and 16 with valvular atrial fibrillation (VAF) (control group) were identified.

Data Collected
Patient demographics and diseases, diagnostic tests for atrial fibrillation (AF), antithrombotic drugs and dosage, anticoagulant activity test results, other drugs, and drug allergies were determined by chart review and attending physician response to written communication from the nursing home's medical director and consultant pharmacist.

Main Outcome Measures
Prevalence of NVAF, VAF, and risk factors for thromboembolism and major bleeding, use of warfarin and other antithrombotic drugs for AF, anticoagulation control, and the relationship of warfarin dose with the recommended international normalized ratio (INR) and prothrombin time (PT).

Results
Nonvalvular AF was documented in 7.6% of the patients. Most patients with NVAF were at an increased risk for stroke, yet only 20% without a conventional contraindication to warfarin use experienced anticoagulation; a greater proportion of patients with VAF experienced anticoagulation. The INR was within the recommended range for NVAF over a 6-month period 37% of the time and recommended PT, 52% of the time. An equal percentage of warfarin dose changes occurred in response to a PT ratio outside the recommended range as occurred with an INR outside the recommended range.

Conclusions
Many nursing home patients have NVAF with comorbid conditions that subject them to a greater than average risk for thromboembolic stroke. Warfarin is underused for stroke prophylaxis and often is not used according to the American College of Chest Physician guidelines. Physicians, nurses, and consultant pharmacists must be better informed about (1) known risk factors for thromboembolism and major bleeding to identify patients with AF who will most likely benefit from warfarin therapy, (2) maintaining an INR of 2 to 3, and (3) the need for small warfarin dose adjustments in elderly patients.



Author Affiliations

From the Pharmacy Corporation of America and the College of Pharmacy, the University of Minnesota, Minneapolis (Dr Lackner), and Minnesota Mutual Life, St Paul (Dr Battis).



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence and Quality of Warfarin Use for Patients With Atrial Fibrillation in the Long-term Care Setting
McCormick et al.
Arch Intern Med 2001;161:2458-2463.
ABSTRACT | FULL TEXT  

Warfarin for Stroke Prevention Still Underused in Atrial Fibrillation : Patterns of Omission
Cohen et al.
Stroke 2000;31:1217-1222.
ABSTRACT | FULL TEXT  

Stroke prevention practices in patients with atrial fibrillation and pacemaker therapy: Evidence for under-use of anticoagulation
Carlsson et al.
Europace 2000;2:115-118.
ABSTRACT  

Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study
Go et al.
ANN INTERN MED 1999;131:927-934.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation
Gage et al.
Stroke 1998;29:1083-1091.
ABSTRACT | FULL TEXT  

Recent National Patterns of Warfarin Use in Atrial Fibrillation
Stafford and Singer
Circulation 1998;97:1231-1233.
ABSTRACT | FULL TEXT  

Atrial Fibrillation and Stroke Prevention With Warfarin in the Long-term Care Setting
Gurwitz et al.
Arch Intern Med 1997;157:978-984.
ABSTRACT  

Anticoagulant Therapy in Patients Aged 80 Years or More With Atrial Fibrillation: More Caution Is Needed
Ackermann
Arch Fam Med 1997;6:105-110.
ABSTRACT  

New Knowledge, Old Patients
Brechtelsbauer
Arch Fam Med 1995;4:1014-1016.
ABSTRACT  




HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.